Diabetes Therapy
ISSN 1869-6953 · Adis, Springer Healthcare · United Kingdom · active 2010–2026
Metrics
- Best Scimago quartile (2025)
- Q1
- Cites per paper (2y)
- 5.5
- SJR
- 1.137
- h-index
- 77
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric (how the two differ). Citation rates differ enormously between fields, so compare within a discipline. What the other figures mean: journal quartile, SJR, h-index and article processing charge.
Data as of 25 October 2026 (venue index build).
Scimago Journal Rank 2025
In the Scimago Journal Rank 2025 edition, Diabetes Therapy is Q1 in 1 of its 2 subject categories and Q2 in the other 1. Its best category quartile is Q1.
| Subject category | Quartile | Rank in category |
|---|---|---|
| Internal Medicine | Q1 | #43 of 181 |
| Endocrinology, Diabetes and Metabolism | Q2 | #73 of 249 |
- Cites per document (2 years, Scopus)
- 4.05
- Documents indexed in 2025 (Scopus)
- 143
The quartile is the one Scimago prints for each category. Rank is the journal's position by SJR among the journals Scimago lists in that category (#1 is the highest); “—” means we hold no rank consistent with that quartile. The document count is what Scopus indexed that year, which can be lower than a journal's full output. Source: SCImago Journal Rank 2025 edition, from Scopus data (scimagojr.com, CC BY-NC).
Diabetes Therapy is Q1 in 1 of its 2 Scimago subject categories (2025 edition; best category Internal Medicine: Q1, #43 of 181), with SJR 1.137 (Scimago) and an h-index of 77 (OpenAlex). Listed in DOAJ, Scopus, Web of Science, PubMed.
Is this the right journal for your paper?
The AI Journal Finder ranks the best-matched journals for your paper’s topic — with tier, open access, citation rate and predatory flags. Free to start.
Responding time
- Submission to publication
- ~6 wkDOAJ self-reported
Turnaround figures are indicative, not a guarantee: DOAJ values are self-reported by the journal (average weeks, submission to publication); library estimates are medians of the received/accepted dates printed in papers we hold. Editorial times vary by article type and season — confirm on the journal’s own site.
Indexing & access
- Indexed in
- DOAJScopusWeb of SciencePubMed
- Access status:
- gold. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
Scope
Frequently asked
Is Diabetes Therapy a predatory journal?
Our screening does not flag Diabetes Therapy. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in DOAJ, Scopus, Web of Science, PubMed, which is a positive signal.
Is Diabetes Therapy indexed in Scopus or Web of Science?
Per our venue index, Diabetes Therapy appears in: DOAJ, Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is the impact factor of Diabetes Therapy?
Papers in Diabetes Therapy are cited about 5.5 times each within two years of publication, and Scimago places it in Q1, with an h-index of 77. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.
What Scimago quartile is Diabetes Therapy (Q1, Q2, Q3, or Q4)?
In the Scimago Journal Rank 2025 edition, Diabetes Therapy is Q1 in 1 of its 2 subject categories and Q2 in the other 1. By category: Internal Medicine: Q1, #43 of 181; Endocrinology, Diabetes and Metabolism: Q2, #73 of 249. Its best category quartile is Q1. Quartiles split the journals in a subject category into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; Diabetes Therapy is cited about 5.5 times per paper over two years, with an h-index of 77.
What is the Web of Science (JCR) quartile of Diabetes Therapy?
The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for Diabetes Therapy. The open equivalent is its best Scimago quartile, Q1 in Internal Medicine, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.
Is Diabetes Therapy open access?
Our index records its access status as "gold". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.
How long does Diabetes Therapy take to publish a paper?
Submission to publication for Diabetes Therapy takes about ~6 wk — DOAJ self-reported. Treat it as indicative rather than a guarantee: editorial times vary by article type, reviewer availability and season, and a self-reported figure is the journal's own. We do not hold a peer-review acceptance rate for Diabetes Therapy.
Ready to submit? Tools for your next paper
Similar venues
- Journal of EndocrinologyQ1 · Bioscientifica
- The Journal of Clinical Endocrinology & MetabolismQ1 · Oxford University Press
- Diabetes Technology & TherapeuticsQ1 · Mary Ann Liebert, Inc.
- Endocrine PathologyQ1 · Springer Science+Business Media
- Current Medical Research and OpinionQ2 · Taylor & Francis
- The Science of Diabetes Self-Management and CareQ1 · SAGE Publishing
Compare it with its peers: Ranked Endocrinology, Diabetes and Metabolism journals — ranked by Scimago quartile and cites per paper, predatory venues excluded.